Quantum-Si Incorporated - QSI STOCK NEWS

Quantum-Si (QSI) announced its relocation to new headquarters at the Winchester Works site in Guilford, Connecticut, in the first half of 2022. The 65,000 square-foot facility will enhance R&D and office space, furthering QSI's mission to advance protein sequencing technology. This strategic move follows the opening of a San Diego facility in late 2021, emphasizing QSI's commitment to growth in vital life sciences hubs. The CEO highlighted the importance of these campuses for talent recruitment ahead of the platform's commercial launch.

Quantum-Si, a life sciences tools company specializing in protein sequencing, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The company's management will present virtually on January 12, 2022, at 4:30 PM ET. A live webcast will be accessible through Quantum-Si's investor website, with a replay available afterward. Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si aims to innovate proteomics using a unique semiconductor chip for next-generation protein sequencing and advancements in drug discovery.

Detect, Inc. has launched its FDA-authorized PCR-quality at-home Covid-19 test for consumer purchase at $49. This rapid test is at least 50 times more sensitive than leading antigen tests, delivering results in one hour, with an accuracy agreement of 97.3% against highly sensitive PCR tests. The company appointed consumer tech veteran Hugo Barra as CEO to enhance its growth. Detect also offers a telehealth service for certified results at $20. They have raised $110M in funding and received an $8.1M contract from the NIH to scale manufacturing.

Quantum-Si (Nasdaq: QSI) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of its annual reconstitution, effective December 20, 2021. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities based on specific eligibility criteria such as market capitalization and trading volume. Quantum-Si specializes in protein sequencing technology, aiming to enhance drug discovery and diagnostics through its innovative semiconductor chip designed for single molecule sequencing.

Quantum-Si (NASDAQ: QSI) announced its Q3 2021 financial results, reporting a net loss of $18.1 million, up from $8.6 million in Q3 2020. Operating expenses surged to $25.2 million, largely due to increased hiring and efforts in product development. The Early Access program expanded to ten sites, enhancing collaboration with academia and industry. The company also aims to bolster its chip production capabilities by acquiring Majelac Technologies. As of September 30, 2021, Quantum-Si has $500.2 million in cash and equivalents, positioning it well for future growth.

Quantum-Si (NASDAQ: QSI) has acquired Majelac Technologies LLC, enhancing its semiconductor chip assembly and packaging capabilities. This acquisition aims to secure Quantum-Si's supply chain and support the scaling of its commercialization efforts. CEO John Stark emphasized that in-house chip assembly will expedite operations to meet demand amid global semiconductor supply challenges. The integration of Majelac, known for its quick-turn assembly services, is expected to bolster Quantum-Si's mission to innovate in proteomics research.

Quantum-Si Incorporated (NASDAQ: QSI) announced its participation in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. CEO John Stark and CFO Claudia Drayton will engage in a virtual fireside chat on Thursday, November 18, 2021, at 2:30 p.m. ET. Interested parties can access a webcast on the Investors section of Quantum-Si's website, with a replay available post-event. Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si focuses on advancing proteomics through its unique protein sequencing technology powered by a groundbreaking semiconductor chip.

Detect, Inc. announces that its PCR-quality at-home Covid-19 Test has received Emergency Use Authorization from the U.S. FDA. The test provides results in one hour, making it ideal for home, school, and workplace use. With an overall agreement of 97.3%, a sensitivity of 90.9%, and 100% specificity, it is among the most accurate home tests available. Priced under $50, it stands as the lowest-cost molecular test on the market. The test is designed to detect all current variants of concern and is supported by an $8.1 million NIH contract to scale up manufacturing.

Quantum-Si (NASDAQ:QSI) will report its Q3 2021 financial results on November 11, 2021, before market open. CEO John Stark and CFO Claudia Drayton will host a conference call at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update. The call will be accessible via webcast and by phone.